PROJECT STAGE
Lead optimisation
Hit to lead
Screening
Assay Development
Therapeutic area
  • Cancer

Project Aim

To develop an ADC against anaplastic lymphoma kinase 1 (ALK) for the treatment of neuroblastoma

Advantage

Exploits ALK as a tumour marker and is independent of its role in driving disease. Less likely to induce resistance than current therapies

Target Class

Receptor tyrosine kinase

Modality

Antibody drug conjugate

Current Status

Antibody generated and shown to internalise on ALK binding. Conjugation prior to in-vitro proof of concept and humanisation

Intellectual Property

Opportunity to create a protective IPR portfolio

Offering

Licence

Key Contact

  • In submitting your personal data via this form, you consent to being contacted via the details provided so that your enquiry can be responded to. A backup of your data will be held but only authorised individuals will be able to access your data. If you would like your data to be removed, please email support@thewebkitchen.co.uk.
    Please see our Privacy policy in relation to the personal data you submit to us through this page.
  • We would love to send you information about LifeArc news and events. Please let us know if you would like us to contact you by selecting one of the following options:
All Licensing Opportunities